Glaxosmithkline Phar

₹1983.1 10.3 | 0.5%

WEBSITE BSE:500660 NSE : GLAXOSMITH 10 May, 16:01

Market Cap ₹33594 Cr.

Stock P/E 63.5

P/B 21.2

Current Price ₹1983.1

Book Value ₹ 93.6

Face Value 10

52W High ₹2650

Dividend Yield 1.61%

52W Low ₹ 1264.9

Edit Ratio

Glaxosmithkline Phar Research see more...

Overview Inc. Year: 1924Industry: Pharmaceuticals & Drugs

GlaxoSmithKline Pharmaceuticals Ltd is a pharmaceutical enterprise. The Company is engaged in the business of manufacturing, distributing, and trading in prescription drugs. It manufactures medicinal materials used in the manufacture of prescription drugs, inclusive of antibiotics, endocrine products, basic nutrients; opium derivatives; sulpha tablets; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically natural sugar. It gives various prescription drugs, vaccines, and consumer healthcare products. Its medication portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio consists of Ambirix, Cervarix, Fendrix, and Havrix. The Company's products consist of Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health merchandise include Sensodyne, parodontax and Polident. Its manufacturing unit is at Nashik.

Glaxosmithkline Phar Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Glaxosmithkline Phar Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	934	816	810	745	917	802	787	762	957	805
Other Income	15	10	19	28	22	23	28	36	28	28
Total Income	949	826	828	773	939	826	815	798	985	833
Total Expenditure	678	618	634	596	660	574	618	618	668	587
Operating Profit	271	208	194	177	279	252	197	180	318	246
Interest	0	1	0	1	0	0	1	0	0	0
Depreciation	17	18	15	16	16	16	17	16	18	17
Exceptional Income / Expenses	0	-18	30	0	0	-11	10	17	0	-163
Profit Before Tax	253	172	208	160	262	224	190	181	299	65
Provision for Tax	64	33	263	44	69	60	57	49	82	20
Profit After Tax	189	138	-55	116	193	165	133	132	218	46
Adjustments	15	12	1274	3	0	0	0	0	0	0
Profit After Adjustments	204	150	1219	119	193	165	133	132	218	46
Adjusted Earnings Per Share	12.1	8.9	72	7	11.4	9.7	7.9	7.8	12.8	2.7

Glaxosmithkline Phar Profit & Loss

#(Fig in Cr.)	Dec 2012	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	2692	2608	3363	2838	2908	2871	3128	3224	2926	3278	3252	3311
Other Income	224	222	259	123	73	55	102	79	111	76	101	120
Total Income	2916	2830	3622	2961	2982	2926	3230	3303	3036	3354	3352	3431
Total Expenditure	1915	2124	2788	2360	2489	2366	2527	2567	2327	2516	2447	2491
Operating Profit	1001	706	833	601	492	560	703	736	709	838	905	941
Interest	0	0	0	0	0	0	1	6	4	2	2	1
Depreciation	18	20	25	25	26	38	49	83	79	68	66	68
Exceptional Income / Expenses	-148	26	-52	2	46	18	29	-341	-173	12	-1	-136
Profit Before Tax	834	711	756	578	511	540	683	306	454	779	836	735
Provision for Tax	272	230	279	202	174	189	237	213	167	398	229	208
Profit After Tax	562	482	476	376	337	351	445	93	287	381	608	529
Adjustments	0	0	0	0	0	0	0	0	71	1314	3	0
Profit After Adjustments	562	482	476	376	337	351	445	93	358	1695	611	529
Adjusted Earnings Per Share	33.2	28.4	28.1	22.2	19.9	20.7	26.3	5.5	21.1	100	36	31.2

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-1%	0%	3%	2%
Operating Profit CAGR	8%	7%	10%	-1%
PAT CAGR	60%	87%	12%	1%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	55%	11%	9%	5%
ROE Average	28%	21%	18%	20%
ROCE Average	38%	35%	30%	32%

Glaxosmithkline Phar Balance Sheet

#(Fig in Cr.)	Dec 2012	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	2007	1990	1829	2183	2007	2057	2140	1821	1478	2663	1741
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	4	4	3	2	1	1	0	0	0	0	0
Other Non-Current Liabilities	154	155	194	3497	3699	2632	2860	180	179	159	125
Total Current Liabilities	836	889	1107	784	881	2949	2804	1022	1355	1698	1326
Total Liabilities	3002	3037	3133	6465	6588	7639	7804	3023	3012	4520	3193
Fixed Assets	89	100	123	204	253	323	430	757	386	329	329
Other Non-Current Assets	266	313	423	3883	4500	3780	4015	491	423	483	370
Total Current Assets	2647	2624	2587	2372	1833	3531	3356	1775	2023	3708	2494
Total Assets	3002	3037	3133	6465	6588	7639	7804	3023	3012	4520	3193

Glaxosmithkline Phar Cash Flow

#(Fig in Cr.)	Dec 2012	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	374	138	95	115	115	139	201	99	105	405	286
Cash Flow from Operating Activities	314	281	338	139	234	473	409	490	578	811	484
Cash Flow from Investing Activities	-110	189	180	499	301	-104	-153	-57	418	-406	808
Cash Flow from Financing Activities	-441	-494	-497	-638	-511	-307	-358	-428	-696	-524	-1543
Net Cash Inflow / Outflow	-237	-24	21	-0	24	62	-102	6	300	-119	-251
Closing Cash & Cash Equivalent	138	114	116	115	139	201	99	105	405	286	35

Glaxosmithkline Phar Ratios

#	Dec 2012	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	33.17	28.43	28.12	22.2	19.88	20.7	26.29	5.5	21.14	100.04	36.05
CEPS(Rs)	34.22	29.61	29.62	23.68	21.44	22.95	29.16	10.38	21.6	26.5	39.75
DPS(Rs)	50	50	62.5	50	30	35	20	40	30	90	32
Book NAV/Share(Rs)	118.46	117.45	107.96	128.88	118.46	121.44	126.31	107.47	87.26	157.19	102.89
Core EBITDA Margin(%)	28.12	18.02	16.56	16.85	13.97	16.76	19.21	19.55	19.14	21.2	22.54
EBIT Margin(%)	30.21	26.54	21.8	20.4	17.05	17.89	21.84	9.28	14.64	21.73	23.49
Pre Tax Margin(%)	30.2	26.53	21.78	20.38	17.04	17.89	21.82	9.09	14.53	21.67	23.44
PAT Margin (%)	20.34	17.96	13.73	13.25	11.23	11.62	14.24	2.77	9.19	10.59	17.03
Cash Profit Margin (%)	20.98	18.7	14.46	14.13	12.11	12.88	15.79	5.23	11.71	12.49	18.87
ROA(%)	18.82	15.95	15.44	7.84	5.16	4.93	5.77	1.72	9.52	10.11	15.76
ROE(%)	28.5	24.1	24.95	18.75	16.08	17.26	21.22	4.71	17.42	18.39	27.58
ROCE(%)	42.24	35.54	39.53	28.81	24.39	26.56	32.54	15.76	27.74	37.72	38.06
Receivable days	13.29	14.45	10.35	14.59	18.09	19.21	15.6	11.96	18.42	21.37	20.34
Inventory Days	40.86	43.02	38.01	57.97	57.89	55.98	57.56	52.62	60.14	54.91	50.87
Payable days	72.62	81.46	81.61	87.58	79.21	115.38	122.52	106.45	119.53	140.69	143.05
PER(x)	32.65	52.63	60.5	85.59	68.79	50.36	49.44	226.34	68.13	16.62	36.73
Price/Book(x)	9.14	12.74	15.76	14.75	11.54	8.59	10.29	11.59	16.51	10.58	12.87
Dividend Yield(%)	2.31	1.67	1.84	1.32	1.1	1.68	1.54	3.21	2.08	5.41	2.42
EV/Net Sales(x)	6.05	8.94	8	10.85	7.66	5.7	6.67	6.21	7.94	7.84	6.54
EV/Core EBITDA(x)	16.27	33.04	32.29	51.21	45.26	29.21	29.65	27.18	32.8	30.67	23.51
Net Sales Growth(%)	9.64	-3.13	28.96	-15.61	2.49	-1.27	8.94	3.08	-9.27	12.05	-0.8
EBIT Growth(%)	37.94	-14.73	6.23	-23.45	-11.64	5.62	26.49	-54.32	46.6	70.71	7.32
PAT Growth(%)	31.1	-14.28	-1.09	-21.05	-10.46	4.13	26.99	-79.07	208.21	32.55	59.58
EPS Growth(%)	31.1	-14.28	-1.09	-21.05	-10.46	4.13	26.99	-79.07	284.26	373.19	-63.97
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0
Current Ratio(x)	3.16	2.95	2.34	3.03	2.08	1.2	1.2	1.74	1.49	2.18	1.88
Quick Ratio(x)	2.82	2.56	2	2.36	1.6	1.03	1.02	1.26	1.09	1.87	1.53
Interest Cover(x)	2497.59	2146.51	1612.26	1373.88	2045.74	2856.45	1232.59	49.26	129.56	391.29	462.54
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Glaxosmithkline Phar Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	75	75	75	75	75	75	75	75	75	75
FII	2.04	2.18	2.16	2.17	2.29	2.28	2.41	2.5	2.92	3.48
DII	10.73	10.74	10.65	10.54	10.28	10.3	10.25	10.02	8.65	7.9
Public	12.23	12.09	12.19	12.29	12.43	12.43	12.35	12.49	13.43	13.62
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71
FII	0.35	0.37	0.37	0.37	0.39	0.39	0.41	0.42	0.5	0.59
DII	1.82	1.82	1.8	1.78	1.74	1.74	1.74	1.7	1.46	1.34
Public	2.07	2.05	2.06	2.08	2.11	2.11	2.09	2.12	2.27	2.31
Others	0	0	0	0	0	0	0	0	0	0
Total	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 21%
Company is almost debt free.

Cons

Debtor days have increased from 140.69 to 143.05days.
Stock is trading at 21.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Glaxosmithkline Phar News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Glaxosmithkline Phar

Add Watchlist

Glaxosmithkline Phar Research see more...

Overview Inc. Year: 1924Industry: Pharmaceuticals & Drugs

Glaxosmithkline Phar Share Price

Alert Data

Quarterly Price

Peer Comparison

Glaxosmithkline Phar Quarterly Results

Glaxosmithkline Phar Profit & Loss

Growth Rates

Glaxosmithkline Phar Balance Sheet

Glaxosmithkline Phar Cash Flow

Glaxosmithkline Phar Ratios

Glaxosmithkline Phar Shareholding Pattern

Glaxosmithkline Phar News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!